1. Inglewood Lab Q2 Earnings Analysis: Sales Decline, But Operating Profit Increased?

Inglewood Lab reported a 4.0% year-over-year decrease in sales to 70,222 thousand USD in Q2 2025. However, operating profit increased by 26.9% to 10,316 thousand USD, leading to an improved operating margin of 14.7%. Net income decreased by 48.5% to 4,312 thousand USD. The reasons for these fluctuations and the future outlook will be discussed in detail during the IR.

2. Key IR Checkpoints: Focus on These 3 Questions

Pay close attention to the answers to these three questions during the IR:

  • What is the strategy to reverse the declining sales trend? The company’s response to the growth of indie brands and increasing competition is crucial.
  • What is the strategy for improving and maintaining profitability? Specific plans for cost management and efficient resource utilization are necessary.
  • What is the strategy for dealing with exchange rate and interest rate volatility? Risk management strategies for macroeconomic uncertainties are important.

3. Investor Action Plan: What’s Next for the Stock After the IR?

Inglewood Lab’s stock price is likely to fluctuate depending on the content of the IR presentation and the market’s reaction. Investors should carefully analyze the management’s responses during the IR and continuously monitor the feasibility of the company’s business strategies and its ability to adapt to external environmental changes.